| Ytd | 133.10% | |
| 1y | 292.16% |
| Open | 9.78 | Prev Close | 9.15 | Low | 9.04 | High | 10.06 | Mkt Cap | 247.17M |
| Vol | 517.98K | Avg Vol | 588.01K | EPS | -3.54 | P/E | -2.82 | Forward P/E | -3.18 |
| Beta | 2.18 | Short Ratio | 20.47 | Inst. Own | 89.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 8.92 | 200-d Avg | 6.19 | 1yr Est | 21.25 |
ARTV News
SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical
Cracker Barrel (CBRL) stock rises in pre-market trading after reporting better-than-expected Q3 resu
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains
Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meanin
Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combi
Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the
Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Ove
Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and
HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with
Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million priva
RKLB: 8% | Rocket Lab shares are trading higher after the company reported better-than-expected Q1 s
On May 8, 2026, the Company delivered written notice to Leerink Partners LLC ("Leerink") tha
Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.95) per share which missed the
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains
Dow futures up 250 points. Sonoco Products Co (SON) shares down 5.7% in pre-market after reporting l
